KOZARICH JOHN W 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jan 6, 2026
Insider Transaction Report
Form 4
KOZARICH JOHN W
Director
Transactions
- Sale
Common Stock
2026-01-02$186.59/sh−21$3,918→ 44,100 total - Sale
Common Stock
2026-01-02$187.95/sh−91$17,104→ 44,009 total - Sale
Common Stock
2026-01-02$188.96/sh−102$19,274→ 43,907 total - Sale
Common Stock
2026-01-02$190.27/sh−207$39,386→ 43,700 total - Sale
Common Stock
2026-01-02$192.40/sh−46$8,850→ 43,654 total
Footnotes (4)
- [F1]The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $187.6150 to $188.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $188.6000 to $189.3900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $189.7800 to $190.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.